Context Therapeutics Inc. (NASDAQ:CNTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Context Therapeutics Inc. (NASDAQ:CNTX) has earned a consensus recommendation of “Moderate Buy” from the eight research firms that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, six have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $6.60.

CNTX has been the subject of several recent analyst reports. Wall Street Zen raised shares of Context Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Piper Sandler lifted their price target on shares of Context Therapeutics from $4.00 to $7.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Context Therapeutics in a research note on Monday, April 20th. D. Boral Capital reiterated a “buy” rating and set a $9.00 price target on shares of Context Therapeutics in a research note on Tuesday, March 24th. Finally, Lifesci Capital upgraded shares of Context Therapeutics to a “strong-buy” rating in a research note on Monday, February 23rd.

Institutional Investors Weigh In On Context Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Virtu Financial LLC acquired a new stake in Context Therapeutics during the 4th quarter worth $43,000. Sanctuary Advisors LLC acquired a new stake in Context Therapeutics during the 1st quarter worth $51,000. Quadrature Capital Ltd acquired a new stake in Context Therapeutics during the 4th quarter worth $68,000. Citadel Advisors LLC acquired a new stake in Context Therapeutics during the 3rd quarter worth $100,000. Finally, XTX Topco Ltd raised its stake in Context Therapeutics by 858.8% during the 4th quarter. XTX Topco Ltd now owns 101,605 shares of the company’s stock worth $149,000 after acquiring an additional 91,008 shares in the last quarter. 14.03% of the stock is currently owned by institutional investors and hedge funds.

Context Therapeutics Trading Down 7.3%

Context Therapeutics stock opened at $2.16 on Friday. The stock has a market cap of $198.46 million, a P/E ratio of -5.14 and a beta of 1.57. The company has a fifty day simple moving average of $2.62 and a 200-day simple moving average of $1.94. Context Therapeutics has a 12-month low of $0.49 and a 12-month high of $3.62.

Context Therapeutics (NASDAQ:CNTX) last released its quarterly earnings data on Wednesday, May 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $0.03. As a group, sell-side analysts forecast that Context Therapeutics will post -0.35 earnings per share for the current fiscal year.

Context Therapeutics Company Profile

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.